VRTX Jan 2024 250.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:05AM EST. Market open.
| Previous close | 0.2500 |
| Open | 0.2500 |
| Bid | 0.0500 |
| Ask | 0.2000 |
| Strike | 250.00 |
| Expiry date | 2024-01-19 |
| Day's range | 0.2500 - 0.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 290 |
Motley FoolCould CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Biotech companies CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX) are often mentioned in the same sentence. Vertex is a much larger company with proven innovative abilities, and it has generated strong and consistent revenue, earnings, and stock-market performance in the past decade. CRISPR is a much younger company with a much shorter track record, but could it one day become as successful as its larger partner?
ZacksArcturus' (ARCT) CF Drug Gets FDA's Orphan Status, Stock Up
Arcturus (ARCT) rises 8% as the FDA grants Orphan Drug Designation for its product candidate, ARCT-032, for the treatment of cystic fibrosis.
Simply Wall St.Vertex Pharmaceuticals (NASDAQ:VRTX) shareholders have earned a 14% CAGR over the last five years
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...
© 2023 Yahoo. All rights reserved.